Condition: Diabetic Kidney Disease · Type 1 Diabetes · Sponsor: University of Washington
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measured by MRI from baseline to 26 weeks in type 1 diabetes. Other objectives are to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
This description comes directly from the study's public registry record.
Ernest Ayers, MSPH · 206-685-1423 · ayerse@uw.edu
Leila Zelnick, PhD · 206-543-2981 · lzelnicke@uw.edu
Always discuss trial participation with your own doctor first.
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
| Providence Sacred Heart Medical Center | Spokane, Washington, United States | Recruiting |
| Toronto General Hospital, University Health Network | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05822609